Entry Detail



General Information

Database ID:exR0274701
RNA Name:hsa-miR-302c-3p
RNA Type:miRNA
Chromosome:chr4
Starnd:-
Coordinate:
Start Site(bp):112648366End Site(bp):112648388
External Links:hsa-miR-302c-3p



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE22981
Description:Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer
Experimental Design:Cancer vs Control
Case Disease Type:Breast Cancer
Case Disease SubType:Early satge breast cancer
Case Sample:Breast Cancer
Control Sample:Control
Number of Case:20
Number of Control:20
Number of Samples:40





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
MTMR12
chr5
32226994
32312987
-
TXNIP
chr1
145992435
145996579
-
CLU
chr8
27596917
27614700
-
MBP
chr18
76978827
77133683
-
CCNB1
chr5
69167135
69178245
+
SETD7
chr4
139495941
139606699
-
NUP153
chr6
17615035
17706834
-
SEC16A
chr9
136440096
136483759
-
SLAIN2
chr4
48341529
48426201
+
ZSCAN26
chr6
28267010
28278224
+
CUL1
chr7
148697914
148801110
+
TRA2A
chr7
23504780
23532041
-
TEFM
chr17
30897336
30906238
-
CCNG2
chr4
77157207
77433388
+
CDK6
chr7
92604921
92836594
-
FYCO1
chr3
45917899
45995824
-
PSMD5
chr9
120815496
120842951
-
MTFR2
chr6
136231024
136250335
-
VRK1
chr14
96797382
96931722
+
UGP2
chr2
63840940
63891562
+
KMT5B
chr11
68154863
68213828
-
SEMA3C
chr7
80742538
80922359
-
COX7C
chr5
86617928
86620962
+
SRRT
chr7
100875103
100888664
+
BCL7A
chr12
122019422
122062044
+
PDXK
chr21
43719094
43762307
+
MOB1A
chr2
74152528
74178898
-
MSTO1
chr1
155610188
155614971
+
NPC2
chr14
74476192
74494177
-
CAMK2N1
chr1
20482391
20486210
-
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0000943
chr19
47421744
47440665
+
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC011503.2
chr19
23927788
23929287
+
AC125257.1
chr17
41848518
41851447
-
AL049840.4
chr14
103694516
103695050
-
ARHGAP27P1-BPTFP1-KPNA2P3
chr17
64749663
64781707
-
FGD5-AS1
chr3
14920347
14948424
-
MIR17HG
chr13
91347820
91354579
+
NEAT1
chr11
65422774
65445540
+
NORAD
chr20
36045618
36051018
-
SNHG16
chr17
76557764
76565348
+
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE22981
Sample Source:Blood
Source Fraction:Plasma
Platform:GPL8179
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:801
Sample treatment protocol:NA
RNA Extract protocol:Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications.
RNA library preparation protocol:Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).



Reference

PMID:21060830
Title:A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer
Author:Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer.
Journal:PLoS One. 2010 Oct 29;5(10):e13735.
Description:The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.